TERMINATION AND TRANSITION SUPPORT AGREEMENTTermination and Transition Support Agreement • May 30th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS TERMINATION AND TRANSITION SUPPORT AGREEMENT (the “Agreement”) is made as of May 25, 2018 (the “Effective Date”), by and between TITAN PHARMACEUTICALS, INC., a Delaware corporation having its principal office at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080-1921 (“Titan”), and BRAEBURN PHARMACEUTICALS, INC., a Delaware corporation having its principal office at 450 Plymouth Rd., Suite 400, Plymouth Meeting, PA 19462 (“Braeburn”). Each of Titan and Braeburn may be referred to herein as a “Party” and collectively, as the “Parties.”
